Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs PHYSIOSOL IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Intravenous solution for fluid and electrolyte replacement in patients with isotonic or hypotonic dehydration,Maintenance of fluid and electrolyte balance during surgery or in postoperative patients,Vehicle for administration of compatible medications
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Not applicable (physiologic solution); infused electrolytes and water distribute and are eliminated with kinetics dependent on renal function; terminal half-life reflects water turnover (~3-6 days in healthy adults).
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
The acetate and gluconate ions are metabolized in the liver and peripheral tissues, primarily via the tricarboxylic acid cycle, to bicarbonate. Electrolytes (sodium, potassium, calcium, magnesium, chloride) are not metabolized but are excreted or reabsorbed as per physiological needs.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Renal excretion of water and electrolytes; >95% of administered volume is excreted unchanged by kidneys within 24 hours; minimal (<5%) fecal or biliary elimination.
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
Negligible (<1%); electrolytes are not bound to plasma proteins.
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Approximately 0.55 L/kg (total body water); distributes into extracellular fluid (0.2 L/kg) and intracellular water (0.4 L/kg).
Intravenous: 100% (only route of administration).
Intravenous: 100%; oral: 100% (but not relevant as product is for IV use only).
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No dose adjustment required; monitor serum electrolytes and fluid balance closely in renal impairment; adjust infusion rate based on renal function to avoid fluid overload.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
No specific dose adjustment required; monitor serum electrolytes and acid-base balance in severe hepatic impairment.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Intravenous infusion; dosing based on body weight; typical dose: 10-20 m L/kg for acute replacement, then adjust based on maintenance requirements; monitor electrolyte levels.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
Use with caution; start with lower end of dosing range; monitor for fluid overload, electrolyte disturbances, and renal function due to age-related changes.
None.
Not for injection into the epidural, intrathecal, or intra-arterial spaces. Do not administer if solution contains visible particulate matter or is discolored. Use only if solution is clear and container is undamaged.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid administration to prevent hypervolemia and electrolyte disturbances,Contains potassium; use cautiously in patients with hyperkalemia or conditions predisposing to potassium retention,Contains calcium; do not administer simultaneously with blood products through the same IV line due to risk of precipitation
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
Hypersensitivity to any component of the solution,Hyperkalemia,Hypercalcemia,Severe metabolic alkalosis,Patients with significant fluid overload or pulmonary edema,Concomitant administration with blood products via same IV line
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
No specific food interactions. However, consider overall fluid and electrolyte intake from diet, especially sodium and potassium, to avoid imbalances.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. Therefore, it should be used during pregnancy only if clearly needed. No specific fetal risks have been identified for any trimester when used as directed.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
Safety in breastfeeding has not been established. Since Physiosol is a balanced electrolyte solution, it is unlikely to pose significant risk to the nursing infant. However, caution is advised. The milk-to-plasma (M/P) ratio is not available.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
No specific dosing adjustments are required for pregnancy based on pharmacokinetic changes. However, pregnant patients may have increased plasma volume, and fluid and electrolyte requirements should be individualized. Caution is advised in preeclampsia or conditions with fluid overload.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
Physiosol in plastic container is a balanced electrolyte solution for intravenous administration, primarily used for replacement of extracellular fluid losses. Monitor for signs of fluid overload, especially in patients with heart failure or renal impairment. The plastic container may leach phthalates; use with caution in neonates and pregnant women. Do not administer if solution is discolored or contains particulate matter.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing.,Notify your healthcare provider if you experience swelling, shortness of breath, or rapid weight gain.,Do not stop the infusion without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs PHYSIOSOL IN PLASTIC CONTAINER, answered by our medical review team.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. PHYSIOSOL IN PLASTIC CONTAINER is a Irrigation Solution that works by PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and PHYSIOSOL IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. The standard adult dose of PHYSIOSOL IN PLASTIC CONTAINER is: Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and PHYSIOSOL IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. PHYSIOSOL IN PLASTIC CONTAINER is classified as Category C. Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-cont. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.